B
PCVX icon

Braidwell’s Vaxcyte PCVX Stock Holding History

Braidwell’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-222,424
Closed -$18.2M – 75
2024
Q4 		$18.2M Sell
222,424
-75,144
-25% -$7.46M 0.54% 52
2024
Q3 		$34M Sell
297,568
-510,735
-63% -$46M 0.96% 39
2024
Q2 		$61M Sell
808,303
-404,400
-33% -$27.5M 1.91% 19
2024
Q1 		$82.8M Sell
1,212,703
-77,262
-6% -$5.35M 2.67% 9
2023
Q4 		$81M Sell
1,289,965
-329,588
-20% -$17.1M 2.98% 7
2023
Q3 		$82.6M Sell
1,619,553
-102,800
-6% -$5.07M 2.61% 9
2023
Q2 		$86M Buy
1,722,353
+402,375
+30% +$19.1M 2.81% 9
2023
Q1 		$49.5M Sell
1,319,978
-42,300
-3% -$1.79M 1.63% 22
2022
Q4 		$65.3M Buy
+1,362,278
New +$53.5M 2.19% 10

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Braidwell's PCVX Position: Q1 2025 in Review

Braidwell sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 222,424 shares — an estimated $18.2M sold.

Braidwell first reported a position in PCVX in Q4 2022 and held it in 9 quarters. The position peaked at $86M in Q2 2023. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Braidwell reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Braidwell sold 222,424 Vaxcyte shares in Q1 2025, an estimated $18.2M.
  • Braidwell first reported a position in Vaxcyte in Q4 2022 and held it in 9 quarters.
  • Braidwell's Vaxcyte position peaked at $86M in Q2 2023.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.